ABSTRACT

Background:

Psoriasis is an autoimmune chronic inflammatory disorder of the skin with a 2 - 4% frequency of occurrence worldwide. The plaque psoriasis appears to be the most common form of the disease with an 85% frequency of occurrence. The biological drugs are considered as a revolutionary therapeutical treatment of the chronic inflammatory disease common as gastroenterology, rheumatology and dermatology in the last decade.

Material and Methods:

The objective of this study was, firstly the estimation of the Psoriasis Area and Severity Index (PASI) score of the Greek patients.

Results:

The sample consisted of 65 patients (32 men and 33 women) with mean age as 50.2 years. 36.9% of patients (n=24) received the Adalimumab drug for the treatment of psoriasis. Adalimumab received by 33.8% of patients (n = 22) who used the agent Ustekinumab, and finally 29.2% (n=19) of patients used Etanercept. PASI score for the first visit was 5.22, and for the second visit was 3.02.

Conclusion:

Consequently, different treatments affect in a different way the PASI score of the patient. The agent Adalimumab had the greatest statistically significant difference between the PASI score of the first and second visit (first visit's PASI: 5.12, second visit's PASI 2.28).